Incyte

Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update

Retrieved on: 
Thursday, May 4, 2023
AACR, CRPC, Betta, Afatinib, Food and Drug Administration, CD3, Overalls, Survival, RECIST, Cancer, Clinical trial, LGR5, Head, ADT, Research, NSCLC, Lung cancer, Cetuximab, Drug design, Castration, Lilly, Patient, EGFR, MET, Eli Lilly and Company, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Prostate cancer, Bank, Pharmaceutical industry, Medical imaging, Cryptocurrency, Meru Networks, Incyte, HNSCC, Pembrolizumab

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update.

Key Points: 
  • In April, Merus provided an interim clinical update at the AACR Annual Meeting 2023.
  • Merus plans to provide an update in Q3 2023 on the potential registrational path for this program.
  • In April, Merus provided a pre-clinical presentation of MCLA-129 in comparison with amivantamab at the AACR Annual Meeting 2023.
  • The Company plans to provide an initial clinical data update from the expansion cohorts, and a further clinical development strategy update in the second half of 2023.

EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Workforce, Rituximab, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Ruxolitinib, Vincristine, AACR, MorphoSys, Doctor of Philosophy, Significant event audit, JAK, DLBCL, Conference call, Lenalidomide, American Association for Cancer Research, Cyclophosphamide, FSE, Incyte, Sale, ASCO, BET, Prednisone, American Society of Clinical Oncology, Patient, Doxorubicin, Annual general meeting, Webcast, Society, Conference, Safety, Security (finance), Nursing, Beauty salon, Video game, Pharmaceutical industry, Tafasitamab

Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023

Key Points: 
  • Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023
    € 791.5 million in cash and other financial assets as of March 31, 2023
    Conference call and webcast (in English) tomorrow, May 04, 2023, at 2:00pm CEST (1:00pm BST/8:00am EDT)
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the first quarter 2023 (Q1 2022: € 0.7 million).
  • On March 14, 2023, MorphoSys announced that Lucinda Crabtree, Ph.D., will join the company as its Chief Financial Officer and member of the Management Board in the third quarter of 2023 at the latest.
  • Total revenues for the first quarter 2023 were € 62.3 million compared to € 41.5 million for the same period in 2022.

MorphoSys AG Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Workforce, Rituximab, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Ruxolitinib, Vincristine, AACR, MorphoSys, Doctor of Philosophy, Significant event audit, JAK, DLBCL, Lenalidomide, American Association for Cancer Research, Cyclophosphamide, FSE, Incyte, Sale, ASCO, BET, Prednisone, American Society of Clinical Oncology, Patient, Doxorubicin, Annual general meeting, Society, Safety, Beauty salon, Nursing, Video game, Pharmaceutical industry, Tafasitamab

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the first quarter 2023 (Q1 2022: € 0.7 million).
  • On March 14, 2023, MorphoSys announced that Lucinda Crabtree, Ph.D., will join the company as its Chief Financial Officer and member of the Management Board in the third quarter of 2023 at the latest.
  • Total revenues for the first quarter 2023 were € 62.3 million compared to € 41.5 million for the same period in 2022.

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

Retrieved on: 
Monday, May 1, 2023
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Inflammation, Medicine, RAD, Dermatitis, COVID-19, Atopic dermatitis, Acne, Back pain, IGA, Poster, Patient, Common, SE, FRCPC, Itch, Autoimmunity, AD, Upper respiratory tract infection, Headache, Research, Conference, Pharmaceutical industry, Incyte

These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C.

Key Points: 
  • These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C.
  • Results showed that patients with AD treated with Opzelura experienced a rapid and substantial improvement in itch, which was sustained and further improved through 28 days of treatment.
  • "We are pleased that the SCRATCH-AD results further emphasize the rapid impact of Opzelura on itch reduction and reinforce its profile as an effective, well-tolerated topical non-steroidal treatment for AD."
  • “I am encouraged by these results showing rapid and substantial itch reduction among AD patients treated with Opzelura, and its potential to quickly alleviate this burdensome symptom for patients.”

CURE Media Group announces Abbey Kaler, MS, APRN, FNP-C, CMSRN, as winner of 2023 Extraordinary Healer® Award

Retrieved on: 
Thursday, April 27, 2023
Survivor, Bachelor of Science in Nursing, City of Hope National Medical Center, OCN, City of Hope, University, Abbey, Nursing, Friends, Breast cancer awareness, Cancer, Kaler, Woman, Research, Monroe Dunaway Anderson, MD Anderson Cancer Center, APRN, San Antonio River Walk, MS, Riverwalk, City, Patient, SAN, Child, Olympic, San Antonio Marriott Rivercenter, RN, Johnson & Johnson, Oncology nursing, MPH, Ovarian cancer, Health, Astrocytoma, Family, Caregiver, Content, Janssen Pharmaceuticals, Incyte

SAN ANTONIO, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- CURE®, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, survivors and caregivers, has named Abbey Kaler, MS, APRN, FNP-C, CMSRN, the winner of the 2023 Extraordinary Healer award. At an awards ceremony at the San Antonio Marriott Rivercenter on the River Walk, Kaler was recognized for her tremendous dedication, expertise and helpfulness in caring for patients. Shannon Miller, seven-time Olympic medalist and cancer survivor, served as the event’s keynote speaker.

Key Points: 
  • Photo credit: Tammy Blalock
    “We are honored to celebrate the exceptional oncology nurses who demonstrate unwavering commitment to their patients,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences®, the parent company of CURE Media Group.
  • Kaler earned a Bachelor of Science degree in nursing at Baptist Health Sciences University in Memphis, Tennessee.
  • Founded in 2007, the annual Extraordinary Healer award has received hundreds of nominations and it continues to grow each year.
  • The men and women honored by the award have been nominated by colleagues, patients, friends, and family of outstanding oncology nurses throughout the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Incyte Corporation – INCY

Retrieved on: 
Monday, April 24, 2023
Graft-versus-host disease, LLP, INCY, Ruxolitinib, GVHD, Polycythemia vera, New Drug Application, NDA, Incyte, PV, QD, Tablet, AUC, FDA, XR, Pomerantz, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Food, Cryptocurrency

NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (“Incyte” or the “Company”) (NASDAQ: INCY).

Key Points: 
  • NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (“Incyte” or the “Company”) (NASDAQ: INCY).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Incyte and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY

Retrieved on: 
Sunday, April 16, 2023
Graft-versus-host disease, LLP, INCY, Ruxolitinib, GVHD, Polycythemia vera, New Drug Application, NDA, Incyte, PV, QD, Tablet, AUC, FDA, XR, Pomerantz, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Food, Cryptocurrency

NEW YORK, April 16, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (“Incyte” or the “Company”) (NASDAQ: INCY).

Key Points: 
  • NEW YORK, April 16, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (“Incyte” or the “Company”) (NASDAQ: INCY).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Incyte and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY

Retrieved on: 
Sunday, April 9, 2023
Graft-versus-host disease, LLP, INCY, Ruxolitinib, GVHD, Polycythemia vera, New Drug Application, NDA, Incyte, PV, QD, Tablet, AUC, FDA, XR, Pomerantz, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Food, Cryptocurrency

NEW YORK, April 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (“Incyte” or the “Company”) (NASDAQ: INCY).

Key Points: 
  • NEW YORK, April 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (“Incyte” or the “Company”) (NASDAQ: INCY).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Incyte and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Retrieved on: 
Friday, March 31, 2023
Biotechnology, Pharmaceutical, Health, Senior, Forte, Clinical trial, Incyte, Research, Bristol Myers Squibb, Celgene, Acquisition, Cryptocurrency, Pharmaceutical industry

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a business update.

Key Points: 
  • Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a business update.
  • “The Forte team continues to explore additional opportunities for pipeline development to drive long-term value creation.”
    In January, Forte appointed Mr. David Gryska to the Board of Directors.
  • Forte had approximately 21.0 million shares of common stock outstanding as of December 31, 2022.
  • Research and development expenses were $5.6 million and $13.9 million for the years ended December 31, 2022 and 2021, respectively.

Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets

Retrieved on: 
Wednesday, April 5, 2023
Science, Cancer, Inflammation, Research, Doctor of Philosophy, Patient, SAN, Global Research Collaboration for Infectious Disease Preparedness, Pharmaceutical industry, Incyte

SAN DIEGO, April 5, 2023 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced it has entered into a Research Collaboration and License agreement with Incyte to discover and develop targeted protein degraders for novel oncology targets.

Key Points: 
  • "We are pleased to embark on this collaboration with Incyte to identify targeted protein degraders for novel oncology targets.
  • Biotheryx and Incyte share a commitment to finding new, transformative treatment options for people living with cancer," said Philippe Drouet, President and Chief Executive Officer of Biotheryx.
  • "Our PRODEGY platform is designed to increase efficiency in degrader discovery and design, enabling the development of therapies for previously undruggable targets.
  • Under the terms of the agreement, Biotheryx will utilize its distinctive PRODEGY platform to identify and initially develop molecular glue degraders for multiple historically undruggable oncology targets.